FDA Sends PI Warning Letter For Not Checking Trial Participants’ Eligibility
FDA sent a warning letter this month to a Georgia child neurologist because he enrolled clinical trial subjects into a study and an extension without ensuring they met clinical study criteria. The FDA warning letter didn’t have the details of the study that was involved. But the warning letter was sent to Daniel Tarquinio, who […]
Read More »Category : News
FDA Warning Clinical Trial Companies For Not Reporting Trial Results
FDA has restarted the policy of warning companies of $10,000 fines if they don’t report clinical trial results. In this case, they are warning clinical trial biotech company Ocugen. Most of us know Ocugen for attempting to bring a new COVID-19 vaccine to the US from India. The trial that is being questioned by FDA […]
Read More »Category : News
GAO Says FDAers Experienced Political Interference In Scientific Decisions During Trump Era
FDA and CDC employees during the Trump administration told the GAO recently that they didn’t report political interference in their regulatory work because they were afraid of retaliation. This came out in a Government Accountability Office report this week. The FOIA office at FDA released the report and also offered a glimpse of some behind […]
Read More »Category : News
FDA Rejects Teva and MedinCell’s Schizophrenia Drug Application
Teva and French biotechnology company MedinCell have intended to compete in the competitive schizophrenia drug market, but their NDA was recently rejected by FDA. FDA sent both companies a full response letter this month. It rejected their request for drug approval for a subcutaneous version of the drug risperidone. Teva told the media it is […]
Read More »Category : News
Indian API Plant Receives FDA 483
The Indian API company Lupin has been criticized by FDA before. After it was cited for inadequate manufacturing operations and other cGMP violations last summer, the genetics drug company still has not cleaned up its operations. Now Lupin’s API plant in Tarapour, India has been hit by an FDA 483 after an FDA inspection from […]
Read More »Category : News
Questions Remain After FDA Offers New Designation To Medical Device Manufacturers
In 2017, FDA launched a new regulatory program to speed up the development of medical devices. It’s estimated the program has helped a minimum of 45 medical devices come to market. It is believed more than 650 medical devices have what is known as ‘breakthrough designation’, which means FDA thinks the device could be more […]
Read More »Category : News
FDA Appears To Be Tightening Regulations For Drug Approvals
In a recent endometriosis application for Myfembree by Myovant and Pfizer, FDA included language that is being seen more often, according to pharmaceutical experts. In the FDA notice, the agency noted deficiencies that prevent discussion of labeling or post-marketing requirements and commitments. This might look like gobbledygook, but some industry analysts are starting to see […]
Read More »Category : News
2 US Drug Manufacturers Get FDA Warning Letter For Poor Investigations, Lax Testing and Validation
Two US drug manufacturers were hit with an FDA warning letter recently for cGMP violations connected to inadequate investigations, sloppy testing of incoming ingredients, as well as improper ethanol screening. Other FDA issues were related to improper validation of drug manufacturing processes, and both companies were hit with repeat violations. The FDA warning letters were […]
Read More »Category : News
FDA Issues Device Cybersecurity Draft Guidance
FDA issued a new draft guidance last week that affects medical device cybersecurity. Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions was written to stress how important it is to protect medical devices during the product’s entire life cycle. The new guidance is intended to replace the previous guidance on the […]
Read More »Category : News
FDA Issues Warning Letter To Stem Cell Company For cGMP Violations
FDA issued a warning letter last month to Smart Surgical DBA Burst Biologics for marketing and sending allogeneic stem cell items that are unapproved. The company also had major violations from cGMPs and good tissue practices (CGTP). The FDA warning letter was posted to the agency’s site in February 2022. It follows an FDA inspection […]
Read More »Category : News
